South Africa has announced plans to limit the ability of drug firms to win patent extensions for brand-name drugs by changing or modifying them in minor ways. Critics allege that such extensions block patients from receiving cheaper and more affordable versions of life-saving medications for such conditions as HIV/AIDS. The South African move comes barely a month after India rejected a patent extension request from Novartis for its best-selling Gleevec cancer treatment.
South Africa proposes limiting drug patent extensions
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||